JENNIFER CREASER: Open Payments
NPI 1588772461 · LEWISTON, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$864 in 61 payments from 15 companies in 2025. Trend: 2023 $364 · 2024 $665 · 2025 $864
Food & beverage: $864
| Company | Payments | Amount |
|---|---|---|
| PFIZER INC. | 13 | $150 |
| ABBVIE INC. | 12 | $145 |
| GlaxoSmithKline, LLC. | 16 | $145 |
| Teva Pharmaceuticals USA, Inc. | 2 | $66 |
| Neurocrine BioSciences, Inc. | 2 | $53 |
| Otsuka America Pharmaceutical, Inc. | 2 | $48 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $46 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $42 |
| Lundbeck LLC | 2 | $37 |
| Supernus Pharmaceuticals, Inc. | 1 | $32 |
Products named: TRELEGY ELLIPTA, NURTEC ODT, QULIPTA, REXULTI, AUSTEDO XR, INGREZZA, CAPLYTA, JARDIANCE.
Industry payments across ID — which companies pay providers there.
